



NIH Research on the Health Effects of Diethylstilbestrol

Prepared by

The _____, Office of the Director

In collaboration with

The National Cancer Institute

The National Institute of Environmental Sciences

National Institutes of Health

Department of Health and Human Services

August 2011



Report Compiled by:

Indira P. Jevaji, M.D., M.S.L.

Senior Medical Officer

Office of Research on Women's Health

Janine A. Clayton, M.D., Deputy Director

Office of Research on Women's Health

Vivian W. Pinn, M.D., Director

Office of Research on Women's Health

The ORWH acknowledges the intramural and extramural program staff of the National Cancer Institute and the National Institute of Environmental Health Sciences for their assistance in the development of this report.

Introduction

The effects of diethylstilbestrol (DES) on the health of women and their offspring have long been a research focus at the National Institutes of Health (NIH). This report is an overview of NIH research related to DES that is primarily conducted or supported by the National Cancer Institute (NCI) and the National Institute of Environmental Health Sciences (NIEHS). The Office of Research on Women's Health (ORWH) appreciates the assistance of the NCI and NIEHS in the preparation of this report.

Summaries of DES research funded by NCI and NIEHS for FY2010 are included in this report, which will be posted on the ORWH website at <http://orwh.od.nih.gov/>.

Background

Diethylstilbestrol, a potent synthetic estrogen first synthesized in 1938, was extensively prescribed world-wide to pregnant women from the 1940s-1970s with the mistaken belief that it could prevent miscarriages and other complications of pregnancy. It was initially given to women with at-risk pregnancies, but ultimately it was also prescribed for normal pregnancies.

In 1971, Herbst¹ reported a strong association between DES use in pregnancy and the occurrence of vaginal clear cell adenocarcinoma (CCA) in a small number (<0.1%) of adolescent daughters of women who took it while pregnant. DES was later associated with frequent non-cancer reproductive problems in DES-exposed daughters; reproductive tract malformations and dysfunction, poor pregnancy outcome, ectopic pregnancies, and premature labor and births have been reported. As DES-daughters age, they may have an increased incidence of uterine fibroids, and may be more susceptible to breast cancer than their unexposed, age-matched counterparts. DES-exposed daughters >40 years of age, exhibit a statistically significant increased risk of developing breast cancer; this risk is even more pronounced in DES-women over 50 years of age, though the small sample size at this age limits statistical significance. DES-exposed mothers also are at increased risk for breast cancer.

¹ Herbst, AL, Ulfelder H, Poskanzer, DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. *N Engl J Med* 284(15):878-81; 1971. [Abstract] (<http://www.nejm.org/doi/full/10.1056/NEJM197104222841604>)

Prenatally DES-exposed sons have a range of reproductive tract problems including malformations (hypospadias, microphallus, and retained testes) and increased genital/urinary inflammation. Animal models initially developed at NIEHS² have demonstrated a range of DES effects in offspring exposed in utero, including reproductive dysfunction, immune system changes, behavioral and sexual abnormalities, and increases in various reproductive and breast cancers. Multigenerational adverse effects have also been observed in prenatally DES exposed animals.

Current NIH research on DES is primarily funded by the NCI and the NIEHS, through both intramural and extramural programs. Specific details about FY 2010 DES research conducted at NIH are available at the following website:

[http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2010&ARRA=N&DCat=Diethylstilbestrol \(DES\)](http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2010&ARRA=N&DCat=Diethylstilbestrol%20(DES)). Additional information about NIH-funded projects is available online at <http://projectreporter.nih.gov/reporter.cfm>.

DES Research at NCI

NCI leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers.

1. The Division of Cancer Epidemiology and Genetics, part of the NCI Intramural Research Program, conducted “Continuation Of Follow-Up Of Des-Exposed Cohort,” in collaboration with five field centers. The project reassembled previously studied cohorts of DES-exposed and unexposed mothers, daughters and sons, and identified subjects with documented exposure status who had not been studied previously, through familial links within the cohorts. Standardized baseline questionnaires were mailed to cohort members to ascertain the risk of cancer and other

²Newbold, RR. Lessons learned from perinatal exposure to diethylstilbestrol. *Tox. Applied Pharm* 199; 142-150; 2004.

disorders. Pathology reports were collected for reported cancers and preneoplastic conditions. Four separate phases of follow-up have been conducted. The purpose of this study is to continue the follow-up through mailed questionnaires and medical record collection, which was begun during the first phase of the study. DES-exposed daughters may be at higher risk of breast, endometrial, and ovarian cancers. DES is a potent estrogen and exposure to high levels of endogenous estrogen in utero is hypothesized to increase the risk of these cancers. Cancer risk in DES-exposed sons will also continue to be assessed, especially for increased risks of prostate cancer. As the offspring who were exposed to DES in utero are currently reaching their late forties, when cancer rates begin to rise, it is important to continue the follow-up of these cohorts to determine if there are long-term increases in cancer risk.

To date the study has identified excess female breast cancer after age 40 that shows a dose-response effect, as well as increased risk for high-grade lesions of the cervix and vagina. The concern over other hormone-related cancers has not been addressed due to small numbers of cases. In the sons, investigators observed excess risk for urogenital anomalies and infertility, and likely excess of testicular cancer.

To examine the effects in the third generation (offspring of women exposed in utero to DES), investigators assembled a small cohort of granddaughters in 2000. Given their average age, there have been few relevant health outcomes. However, investigators did find an elevated risk for infertility. Though not statistically significant, this outcome was also seen in DES-daughters. In addition, there were three cases of ovarian cancer in the granddaughters, with substantially less than one expected. While both of these observations remain difficult to interpret, they have added some urgency to expand the cohort and continue to follow-up.

A list of Principal Investigators and organizations where the study is being conducted is below:

Robert Hoover, Division of Cancer Epidemiology and Genetics, NCI

Arthur Herbst, University of Chicago

Julie Palmer, Boston University Medical Campus

William Strohsnitter, Tufts Medical Center

Linda Titus-Ernstoff, Dartmouth College

More information on the DES Follow-up Study:

DES Follow-up Study Homepage: <http://www.desfollowupstudy.org/index.asp>
DES Follow-up Study Newsletter:
http://www.desfollowupstudy.org/2010_Newsletter.pdf
DES Follow-up Study:
<http://www.cancer.gov/clinicaltrials/search/view?cdrid=636988&version=HealthProfessional&protocolsearchid=9378810>

2. NCI's Division of Cancer Epidemiology and Genetics also supports another project, "Early Life Exposures and Subsequent Cancer Risk," conducted by principal investigator Robert Hoover. The purpose of this study is to continue the diethylstilbestrol (DES) follow-up, by means of mailed questionnaires and medical record collection. Concern has arisen that DES-exposed daughters may be at higher risk of breast, endometrial and ovarian cancers. Exposure to high levels of endogenous estrogen in utero has been hypothesized to increase the risk of these cancers and DES is a potent estrogen. Cancer risk in the sons will also continue to be assessed, especially for increased risks of prostate cancer. Since the offspring who were exposed to DES in utero are currently reaching their late forties, when cancer rates begin to rise, it is important to continue the follow-up of these cohorts to determine if there are long-term increases in cancer risk. The project is also examining other pregnancy conditions associated with altered hormonal environments to help inform studies of risks associated with DES exposure.

Maternal and cord blood samples from monochorionic twin, dichorionic twin and singleton pregnancies of similar gestational age will be collected to quantify differences in concentrations of several hormones and other pregnancy products including estriol, estradiol, estrone, testosterone, androstenedione, dehydroepiandrosterone (DHEA), DHEA-sulfate, progesterone, AFP, prolactin, IGF and IGF-binding protein. Data from medical records and pathology reports will be abstracted to provide information on the mother, baby, pregnancy and placenta.

In collaboration with NICHD on a study of preeclampsia conducted at Louisiana State University Health Sciences Center, blood samples are being collected from mothers and from umbilical cords with and without preeclampsia. The relationship of pregnancy hormone levels and preeclampsia will be analyzed.

In this study using data from a cohort study of preeclamptic and uncomplicated pregnancies at the University of Pittsburgh, the investigators are analyzing maternal and

cord blood samples from preeclamptic and normal pregnancies of similar gestational age to quantify differences in levels of various hormones. The investigators will evaluate associations of several maternal, perinatal and pregnancy factors, such as maternal age and birth weight, with hormone levels in normal pregnancies. In addition, the investigators will determine how well maternal levels represent levels in cord blood. Umbilical cord blood samples were collected from 75 pregnancies in Boston, MA and 175 in Shanghai, China. Pregnancy hormone concentrations will be determined and correlated with putative breast cancer risk factors. The Norwegian birth and cancer registries will be used to investigate the association of several pregnancy and perinatal factors and risk of cancer in adult offspring.

Online Resources from NCI

NCI hosts two Web sites with consumer-oriented information about DES.

First, NCI's factsheet on DES (below) answers 12 frequently asked questions and answers about the drug, including descriptions of the possible health effects of DES, summaries of current research on DES and resources for DES-exposed individuals.

The factsheet is available online at <http://www.cancer.gov/cancertopics/factsheet/Risk/DES>

NCI's Web page also contains information about behaviors, exposures, and other factors that can influence the risk of cancer, including hormones such as DES. NCI's cancer topics Web page for DES contains several links to pertinent information on DES from resources around NIH and other HHS operating divisions. It is available online at <http://www.cancer.gov/cancertopics/causes/des>

Scientific Articles from NCI

The NCI's Division of Cancer Epidemiology and Genetics, along with its collaborators, has published DES findings in peer-reviewed journal articles referenced below.

2010

1. Palmer, J.R., Herbst, A.L., Noller, K.L., Boggs, D.A., Troisi, R., Titus-Ernstoff, L., Hatch, E.E., Wise, L.A., Strohnsnitter, W.C., Hoover, R.N. Urogenital Abnormalities in Men Exposed to Diethylstilbestrol in Utero. *Environ Health* 2009;8:37.
2. Hatch, E.E., Troisi, R., Wise, L.A., Titus-Ernstoff, L., Hyer, M., Palmer, J.R., Strohnsnitter, W.C., Robboy, S.J., Anderson, D., Kaufman, R., Adam, E., Hoover, R.N. Preterm Birth, fetal growth, and Age at Menarche among women exposed prenatally to diethylstilbestrol (DES). *Reprod Toxicol* 2010;31:151-7.
3. Strohnsnitter, W.C., Noller, K.L., Troisi, R., Robboy, S.J., Hatch, E.E., Titus-Ernstoff, L., Kaufman, R.H., Palmer, J.R., Anderson, D., Hoover, R.N. Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol. *J Rheumatol.* 2010;37:2167-73.
4. Titus-Ernstoff, L., Troisi, R., Hatch, E.E., Palmer, J.R., Hyer, M., Kaufman, R., Adam, E., Noller, K., Hoover, R.N. Birth defects in the sons and daughters of women who were exposed in utero to diethylstilbestrol (DES). *Int J Androl.* 2010;33:377-84.

2008

1. Camp EA, Coker AL, Troisi R, Robboy SJ, Noller KL, Goodman K, Titus-Ernstoff L, Hatch EE, Herbst AL, Kaufman RH, Adam E. Cervical Screening and General Physical Exam Behaviors of Women Exposed In-utero to Diethylstilbestrol. *Journal of Lower Genital Tract Disease* 2008;12:111-7.
2. Strohnsnitter WC, Hatch EE, Hyer M, Troisi R, Kaufman RH, Robboy SJ, Palmer JR, Titus-Ernstoff L, Anderson D, Hoover RN, Noller KL. The association between in utero cigarette smoke exposure and age at menopause. *Epidemiology* 2008;167:727-733.
3. Titus-Ernstoff L, Troisi R, Hatch EE, Palmer J, Hyer M, Wise L, Kaufman R, Adam E, Strohnsnitter W, Noller K, Herbst AL, Cole B, Gibson-Chambers J, Hartge P, Hoover RN. Cancer Occurrence in Offspring of Women Exposed *in utero* to Diethylstilbestrol (DES). *Epidemiology* 2008;19:251-257.

2009

1. Camp EA, Coker AL, Robboy SJ, Noller KL, Goodman KJ, Titus-Ernstoff L, Hatch EE, Herbst AL, Troisi R, Kaufman RH, Adam E. Breast cancer screening in women exposed in-utero to diethylstilbestrol. *Breast Cancer Screening in Women Exposed In Utero to Diethylstilbestrol. Journal of Women's Health* 2009;18:547-552.

2007

1. Troisi R, Hatch EE, Titus-Ernstoff L, Hyer M, Palmer J, Robboy S, Strohsnitter WC, Kaufman R, Herbst A, Hoover RN. Cancer Risk in Women Prenatally Exposed to Diethylstilbestrol. *Int J Cancer* 2007;121:356-60.
2. Wise L, Titus-Ernstoff L, Palmer JR, Hatch EE, Perez KM, Strohsnitter W, Kaufman R, Anderson D, Hoover RN, Troisi R. Time to pregnancy, offspring sex ratio, and other fertility outcomes in men exposed prenatally to Diethylstilbestrol (DES) *Am J Epidemiol* 2007;166:765-74.
3. Troisi R, Titus-Ernstoff L, Hyer M, Hatch E, Robboy S, Strohsnitter W, Palmer J, Øglænd B, Adam E, Kaufman R, Herbst AL, Hoover RN. Preeclampsia Risk in Women Exposed Prenatally to Diethylstilbestrol (DES). *Obstet Gynecol* 2007;110:113-20.
4. Wise LA, Palmer JR, Hatch EE, Troisi R, Titus-Ernstoff L, Herbst AL, Kaufman R, Noller KL, Hoover RN. Secondary sex ratio among women exposed to diethylstilbestrol in utero. *Environ Health Perspect.* 2007;115:1314-9.

2006

1. Hatch EE, Troisi R, Wise LA, Hyer M, Palmer JR, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Adam E, Noller KL, Herbst AL, Robboy S, Hartge P, Hoover RN. Age at Natural Menopause in Women Exposed to Diethylstilbestrol in Utero. *Am J Epidemiol* 2006;164:682-688.
2. Troisi R, Hatch EE, Titus-Ernstoff L, Palmer JR, Hyer M, Strohsnitter W, Robboy SJ, Kaufman RH, Herbst AL, Adam E, Hoover RN. Birth Weight and Breast Cancer Risk in Women Exposed and Unexposed to DES *In Utero*. *Br J Cancer* 2006;94:1734-7.
3. Palmer JR, Wise LA, Hatch EE, Troisi R, Titus-Ernstoff L, Strohsnitter W, Kaufman R, Herbst AL, Noller KL, Hyer M, Hoover RN. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomarker Prev* 2006;15:1509-14.
4. Titus-Ernstoff L, Troisi R, Hatch EE, Wise L, Palmer J, Hyer M, Kaufman R, Adam E, Strohsnitter W, Noller K, Herbst AL, Gibson-Chambers J, Hartge P, Hoover RN. Menstrual and Reproductive Characteristics of Women whose Mothers were Exposed to DES *in utero*. *Int J Epidemiol* 2006;35:862-8.
5. Titus-Ernstoff L, Troisi R, Hatch EE, Palmer JR, Wise LA, Ricker W, Hyer M, Kaufman R, Noller K, Herbst AL, Hartge P, Hoover RN. Mortality in Women given Diethylstilbestrol (DES) During Pregnancy. *Br J Cancer* 2006;95:107-111.

6. Larson PS, Ungarelli RA, de Las Morenas A, Cupples LA, Rowlings K, Palmer JR, Rosenberg CL. In utero exposure to diethylstilbestrol (DES) does not increase genomic instability in normal or neoplastic breast epithelium. *Cancer*. 2006;107:2122-6.

2005

1. Wise LA, Palmer JR, Rowlings K, Kaufman RH, Herbst AL, Noller KL, Titus-Ernstoff L, Troisi R, Hatch EE, Robboy SJ. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure. *Obstet Gynecol* 2005;105:167-73.
2. Strohsnitter WC, Noller KL, Titus-Ernstoff L, Troisi R, Hatch EE, Poole C, Glynn R, Hsieh C-C. Breast cancer incidence in women prenatally exposed to maternal cigarette smoke. *Epidemiology* 2005;16:342-45.
3. Perez KM, Titus-Ernstoff L, Hatch EE, Troisi R, Wactawski-Wende J, Palmer JR, Noller K, Hoover RN; National Cancer Institute's DES Follow-up Study Group. Reproductive outcomes in men with prenatal exposure to diethylstilbestrol. *Fertil Steril* 2005;84:1649-56.
4. Palmer JR, Wise LA, Robboy SJ, Titus-Ernstoff L, Noller KL, Herbst AL, Troisi R, Hoover RN. Hypospadias in sons of women exposed to diethylstilbestrol in utero. *Epidemiology* 2005;16:583-6.

2003

1. Titus-Ernstoff L, Perez K, Hatch EE, Troisi R, Palmer JR, Hartge P, Hyer M, Kaufman R, Adam E, Strohsnitter W, Noller K, Pickett K, Hoover R. Psychosexual characteristics of men and women exposed prenatally to Diethylstilbestrol. *Epidemiology* 2003; 14:155-60.

2002

1. Kaufman RH and Adam E. Findings in female offspring of women exposed in-utero to diethylstilbestrol. *Obstet Gynecol* 2002;99:197-200.
2. Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, Noller KL, Herbst AL, Rao RS, Troisi R, Colton T, Hoover RN. Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). *Cancer Causes Control* 2002;13:753-8.

2001

1. Palmer JR, Hatch EE, Rao RS, Kaufman RH, Herbst AL, Noller KL, Titus-Ernstoff L, Hoover RN. Infertility among Women Exposed Prenatally to Diethylstilbestrol. *Am J Epidemiol* 2001;154(4):316-321.

2. Strohsnitter WC, Noller KL, Hoover RN, Robboy SJ, Palmer JR, Titus-Ernstoff L, Kaufman RH, Adam E, Herbst AL, Hatch EE. Cancer risk in men exposed in utero to diethylstilbestrol. *J Natl Cancer Inst* 2001;93(7):545-51.
3. Titus-Ernstoff L, Hatch EE, Hoover RN, Palmer J, Greenberg ER, Ricker W, Kaufman R, Noller K, Herbst AL, Colton T, Hartge P. Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy. *Brit J Cancer* 2001;84(1):126-133.
4. Hatch EE, Herbst AL, Hoover RN, Noller KL, Adam E, Kaufman RH, Palmer JR, Titus-Ernstoff L, Hyer M, Hartge P, Robboy SJ. Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States). *Cancer Causes Control* 2001;12:837-45.

2000

1. Hatch EE, Herbst AL, Hoover RN, Noller KL, Adam E, Kaufman RH, Palmer JR, Titus-Ernstoff L, Hyer M, Hartge P, Robboy SJ. Incidence of squamous neoplasia of the cervix and vagina in DES-exposed daughters. *Ann Epidemiol* 2000;10(7):467.
2. Kaufman RH, Adam E, Hatch EE, Noller K, Herbst AL, Palmer JR, Hoover RN. Continued follow-up of pregnancy outcomes in diethylstilbestrol-exposed offspring. *Obstet Gynecol* 2000;96(4):483-9.

1998

1. Hatch EE, Palmer JR, Titus-Ernstoff, Noller KL, Kaufman RH, Mittendorf R, Robboy SJ, Hyer M, Cowan CM, Adam E, Colton T, Hartge P, Hoover RN. Cancer risk in women exposed to diethylstilbestrol in utero. *JAMA* 1998;280(7):630-4.

DES Research at NIEHS

The NIEHS supports research to understand the effects of the environment on human health. The mission of NIEHS is to reduce the burden of human illness and disability by understanding how the environment influences the development and progression of human disease. The NIEHS conducts DES research through its Intramural Division, and the Institute supports and funds meritorious DES research through its Division of Extramural Research and Training.

1. DES research through the NIEHS Intramural Division

DES has been the focus of experimental animal studies at NIEHS for more than 30 years. NIEHS researchers developed a rodent model of prenatal DES-exposure that proved useful in replicating and predicting adverse health effects in prenatally exposed men and women. This experimental model has been used world-wide to study mechanisms involved in DES-toxicities, and adverse effects of less potent environmental estrogens.

In addition, NIEHS Epidemiology Branch led the DES Study; a follow-up of the Dieckmann³ randomized clinical trial of DES conducted in the early 1950s at the University of Chicago. A total of 848 boys and 805 girls were born to women in the Dieckmann study, half of whom were exposed to high levels of DES during pregnancy and the other half of whom received placebo.

When DES was identified in 1971 as a transplacental carcinogen (Herbst 1971), the University of Chicago attempted to trace the women who participated in the clinical trial, and also their offspring. The daughters and sons were studied for risk of cancer and abnormalities of the reproductive tract. While the daughters continued to be followed, no further contact with the sons was made until 1991, when the NIEHS follow-up study was initiated.

The NIEHS DES study was conducted to pursue hypotheses about possible non-cancer health effects of prenatal estrogen exposure in adults as suggested by laboratory animal studies or clinical reports. Such possible health effects include allergy, infection and autoimmune diseases, cognitive function, male fertility, menstrual cycle function, onset of menopause and age of menarche in the daughters of prenatally-exposed women. Given the estrogen-like activity of several classes of environmental contaminants, the identification of risk in this highly-exposed DES group could suggest more specific hypotheses for the study of the presumably-weaker effects of environmental estrogens. Allen Wilcox, the principal

³ Dieckmann WJ, Davis ME, Rynkiewicz LM, Pottinger RE. Does the administration of diethylstilbestrol during pregnancy have therapeutic value? *Am J Obstet Gynecol* 1953;66:1062-81.

investigator for the study, and his group were able to trace and study 494 sons (253 exposed and 241 unexposed) and 542 daughters (296 exposed and 246 unexposed).

For more information on the NIEHS DES study, visit:

<http://www.niehs.nih.gov/research/atniehs/labs/epi/studies/des/index.cfm>.

1. The NIEHS Division of Extramural Research and Training supports and funds DES research projects at several institutions:

The project “Nongenomic Signaling Mechanisms of Environmental Estrogens,” is conducted by principal investigator Cheryl Watson at the University of Texas Medical Branch Galveston. In this study the investigators will address (1) the structural requirements for activating mERa to generate signals and their linked functions, by comparing the effects of alkylphenol xenoestrogens having varying carbon- chain lengths and structures, and prominent physiological estrogens (E2, estriol, and estrone); (2) active alkylphenols' ability of to act in combination with physiological estrogens via additive, synergistic, and antagonistic mechanisms; and (3) the G protein coupling of these responses. G proteins likely lie upstream of the signaling responses shown by previous work. The investigators seek direct evidence for G protein subtype interactions with mERa via co-immunoprecipitation, use of specific inhibitors, and dominant-negative G protein subtype and decoy interaction peptide approaches. Changes in G protein coupling in response to both physiological estrogens and alkylphenol xenoestrogens will be examined. The investigators' long-term objective is to use the established model system to answer a variety of detailed mechanistic questions about how specific structural features of different physiological estrogens and xenoestrogen subclasses affect actions through the nongenomic pathway and the mERa, and thereby disrupt endocrine processes. The significance of the proposal is to assist in knowing how environmental estrogens disrupt normal signaling and reproductive functions will enable design of new prevention and treatment strategies to deal with their toxicity. Demonstrating their low-dose effects will also guide re-evaluation of Federal regulations setting legal contamination limits for environmental estrogens. The extent and mechanisms by which

environmental estrogens contribute to diseases of estrogen overexposure (e.g., breast and pituitary cancers, infertility) must be understood so that exposures can be limited to safe levels.

The project “DES and the Regulation of the Uterine Cytodifferentiation,” is conducted by principal investigator Liang Ma at Washington University. The molecular mechanism by which DES affects reproductive tract development is unknown. To address this mechanism is important because many synthetic and naturally occurring chemicals mimic estrogen and could affect the health of the next generation in a similar fashion as DES did. This proposal will dissect the genetic pathways affected by DES during female reproductive tract (FRT) development. Preliminary studies show that several developmental control genes are regulated by DES during critical period of uterine cytodifferentiation. In particular, homeodomain protein Msx2 appears crucial in counteracting the effect of DES on the developing FRT as DES induces very dramatic reproductive patterning defects in Msx2 mutants, resulted from altered molecular changes in these mutants. The present grant will continue to test the hypothesis that DES can change uterine epithelial cell fate by affecting genetic pathways governing uterine cytodifferentiation. In aim 1, the role of Msx2 in uterine and vaginal development and DES-induced FRT malformations will be rigorously examined. In aim II, the investigators will use gain and loss of function approaches in vivo to examine whether Klf4 is both necessary and sufficient for DES-induced uterine metaplasia. Finally in aim III, the investigators will test the hypothesis that DES affects luminal epithelial architecture through modulation of the Wnt pathway. By completing these studies, they should be able to build genetic pathways controlling uterine development and address how DES can cause abnormal FRT patterning through modulation of these pathways. Their long term goal is to use mouse as a model to study reproductive tract development and how exogenous factors can influence this process.

The project “Estrogen T-Cell Interactions,” is conducted by principal investigator Prakash Nagarkatti at the University of South Carolina at Columbia. In the current study, the investigators will test the central hypothesis that prenatal exposure to DES alters the positive and/or negative selection of T cells in the thymus leading to generation of

skewed T cell repertoire with enhanced reactivity towards self antigens and decreased response against non-self antigens. In aim# 1, they will investigate whether the regulation of Fas and Fas ligand genes involves estrogen responsive elements (ERE) and other transcription factors. Aim# 2 will test if prenatal exposure to DES alters positive and negative selection of T cells in the thymus and thereby skewing the immune responsiveness of mature T cells to self rather than non-self antigens. Aim# 3 will investigate the role of ER α in DES induced apoptosis and development of autoimmunity. Also, the role of T cell-stromal cell interactions in DES-induced thymocyte apoptosis will be studied. In Aim# 4, the mechanism by which prenatal DES exposure leads to increased susceptibility to autoimmune disease postnatally will be tested. Together, the studies proposed should provide novel information on the mechanism by which prenatal exposure to DES leads postnatally to increased susceptibility to autoimmunity and cancer and to development of potential approaches to prevent such immunotoxicity. Thus, studies are aimed at providing insights into the mechanism by which estrogens mediate their toxic effects on the immune system, thereby leading to the development of strategies for their prevention and treatment.

The project "Alteration of Hox Gene Expression by Endocrine Disrupting Chemicals," is conducted by principal investigator Hugh Taylor at Yale University. The objective of this proposal is to test the hypothesis that the mechanism by which endocrine disrupters affect the development of the reproductive tract is by altering the epigenetic regulation of HOX gene expression. While the initial regulation is mediated through the estrogen receptor (ER α or β), persistent defects in HOX gene expression after exposure to endocrine disrupters suggests epigenetic alteration of HOX expression. In this application the investigators will determine the molecular mechanisms that regulate HOXA10 and HOXA11 as well as identify epigenetic modifications that regulate HOX genes in both mice and humans. First the investigators will characterize the 5' and intronic regulatory regions of HOXA10 and HOXA11 and identify transcription factor binding sites. Based on preliminary data, the investigators hypothesize that these regulatory regions are methylated in response to xenoestrogen exposure. The investigators will identify the potential impact of DES induced methylation on transcriptional regulation of these genes.

Second, they will define the epigenetic changes that lead to persistent Hox gene alteration in the absence of continued exposure in mice. Finally, the investigators will determine if the molecular mechanism by which endocrine disrupters alter HOX gene expression in mice is conserved in humans. The investigators will examine uterine tissue from women with known in utero DES exposure. They have previously shown that Hox genes are necessary for reproductive tract development and that altered Hox expression leads to developmental or functional alterations. Here the investigators expect to demonstrate that endocrine disrupters alter HOX gene expression and will determine the molecular mechanisms that mediate this regulation. No good model exists to explain the mechanism of both the acute and long term diminished HOX gene expression following endocrine disrupter exposure in utero. The investigators hypothesize that the effects are maintained long after exposure through epigenetic mechanisms such as methylation of HOX genes.

The project “Effects of Environmental Estrogen Exposure on the Heart,” is conducted by principal investigator Hong-Sheng Wang at the University of Cincinnati. The goal of the investigators’ proposed study is to elucidate the toxicological effects of exposure to estrogenic xenobiotics on the cardiac system, and to define the underlying pharmacological mechanisms of actions of these agents. They will also investigate the molecular basis for the sex-specific susceptibility to estrogenic xenobiotics-induced cardio-toxic effect. The investigators’ central hypothesis is that E2 and estrogenic EDCs, via activation of membrane associated ER mechanisms, alter cardiac Ca²⁺ handling in a sex-specific manner, and that the actions of at least some estrogenic agents contribute to arrhythmogenesis in female hearts. The investigators propose three Specific Aims to address this hypothesis: Aim 1 is to determine the cellular mechanism(s) underlying the pro- arrhythmogenic effects of EDCs and E2 in rat ventricular myocytes; Aim 2 is to define the molecular basis for the sex-specificity of susceptibility to rapid E2/EDC effects on contractile function and arrhythmogenesis of ventricular myocytes; and Aim 3 is to determine the effects of E2/EDCs on cardiac arrhythmias at the whole organ level, especially during pathologic stress, including catecholamine stimulation and ischemia, and explore potential preventive/therapeutic strategies for protection against such arrhythmias. The proposed study investigates the toxicological effects and underlying

mechanism of exposure to estrogenic xenobiotics and other environmental estrogenic compounds on the cardiac system, particularly in women. These studies have high clinical relevance, particularly with respect to arrhythmias in women in the at risk population. The results will provide critical knowledge for the development of protective measures against environmental estrogenic cardiac risk factors, and the development of novel preventive or therapeutic strategies for cardiac diseases related to these risk factors.

The project “Environmental Epigenetics and Stem/Progenitor Cell Injury,” is conducted by principal investigator Tim Huang at Ohio State University. The investigators propose that immature cells located in the stem/progenitor compartment of the human breast are prime targets of this environmental insult. In Specific Aim 1, primary breast stem/progenitor cells will be exposed to xenoestrogens - diethylstilbestrol, bisphenol A, or 17 β -estradiol in an in vitro system. Global analysis is expected to identify altered methylation status in 1-2% of ~29,000 CpG islands analyzed. These epigenetic events can be the direct results of exposing stem/progenitor cells to xenoestrogens. The epigenetic memory of this injury is then transmitted to differentiated epithelial cells and in turn leads to breast tumorigenesis in a xenograft model. In Specific Aim 2, the investigators will functionally determine whether the prolonged exposure of these endocrine chemicals to stem/progenitor cells disrupt the homeostasis of estrogen signaling and triggers an epigenetic cascade in its downstream targets. Polycomb repressors can be recruited to promoter CpG islands followed by the addition of DNA methyltransferases at these promoters. Acquired DNA methylation, as a result of increased local methyltransferase activities, marks the heritable gene silencing. In Specific Aim 3, the investigators will demonstrate that CpG island hypermethylation induced by xenoestrogen exposure is also observed in clinical samples. The presence of these molecular alterations in primary breast tumors may constitute a xenoestrogen epigenotype(s). In this regard, patients exhibiting this epigenotype are likely exposed to xenoestrogens in their early lives. In addition, low levels of these methylation changes may exist in normal looking mammary epithelial, leaving a field of cancerization in the human breast. This type of CpG island hypermethylation can be tracked as molecular relics using a mathematical modeling approach developed in our laboratory. The

investigators will develop the model further to recreate the history of xenoestrogen-induced breast tumorigenesis, from pre-neoplastic lesions to hyperplasia to carcinoma in situ to invasive carcinoma. Clinical sensitivity and specificity of potential CpG island loci pinpointing the xenoestrogen epigenotype will be provided as a quantitative milestone for this U01 project. These loci are future biomarkers for early breast cancer detection and are putative biosensors to environmental estrogens.

3 Additionally, the NIEHS Division of Extramural Research and Training supported DES research grants utilizing ARRA funds:

The project “Prenatal Developmental Immunotoxicity of Diethylstilbestrol and Methoxychlor,” is conducted by principal investigator Christine Ann Broussard at the University of La Verne. The investigators hypothesize that diethylstilbestrol and methoxychlor (two established EDCs) alter T cell differentiation when present during prenatal immune system development, ultimately leading to inappropriate immune suppression or activation. Using an in vitro prenatal T cell differentiation assay, the experiments in this proposal will determine whether DES and MXC 1) are capable of altering the immune system during embryological development at low doses, 2) are mediating their effects through inhibition of development, or 3) are mediating their effects through induction of apoptosis. This stage-specific analysis of DES and MXC will enhance our understanding of how and when these endocrine disruptors affect the immune system, and will form the basis for assessment of prenatal immunotoxicity of other EDCs and for strategies to prevent immune disease induced by gestational EDC exposure. Endocrine-disrupting chemicals (EDCs) are present throughout the environment, from wastewater releases (e.g. personal care products and pharmaceuticals) to additives in plastic (e.g. bisphenol A) to pesticides used on food crops (e.g. atrazine). Growing evidence suggests that EDCs negatively influence the immune system, potentially leading to immune diseases like asthma, allergies, autoimmune disease, repeated ear infections, and poor vaccine responses, particularly in children. The proposed research will enhance our understanding of how and when EDCs affect the

immune system, and will form the basis for assessment of prenatal immune impacts of EDCs and for strategies to prevent immune disease caused by prenatal EDC exposure.

! "#\$%&(#)*\$Epigenetic Marks of Xenoestrogen Exposure,- \$s conducted by principal investigator David Waxman at Boston University. This application addresses broad Challenge Area (08) Genomics and specific Challenge Topic 08-ES-104, Identification of Alterations in Epigenetic Marks Related to Environmental Exposures. Environmental exposure to foreign chemicals with estrogenic activities is widespread and is proposed to impact adversely on human health. The overall goal of this project is to investigate the hypothesis that perinatal exposure to xenoestrogens induces epigenetic marks associated with permanent changes in expression of key genes controlling female reproductive tract development, which are, in turn, linked to the observed reproductive tract abnormalities and increased incidence of uterine cancer. It is proposed that each xenoestrogen has a unique epigenetic signature as a result of its unique activity as a selective estrogen receptor modulator. These hypotheses will be tested using in utero mouse models of exposure to the xenoestrogens diethylstilbestrol and bisphenol-A. Diethylstilbestrol is a potent xenoestrogen linked to major reproductive tract developmental abnormalities in mouse models and in exposed humans, while bisphenol-A is a weak xenoestrogen that induces more modest reproductive toxicities in the mouse; the consequences of human exposure to the latter chemical are not definitively established. Discovery of the epigenetic signatures that are common, as well as those that are unique, to each xenoestrogen will help elucidate the reproductive toxicology associated with each chemical. These studies will provide important new insight into the mechanisms through which endocrine-active environmental chemicals induce reproductive toxicities, and may, ultimately, lead to new strategies for detection and prevention of adverse effects in exposed individuals. The significance of the studies proposed is major, both in terms of the new scientific knowledge that is expected to result, and for the potential impact on the large number of individuals that are exposed to environmental xenoestrogens. This project investigates the actions of environmental chemicals that exert reproductive toxicities, with special emphasis on environmental estrogens that induce female reproductive tract toxicities in humans and other exposed mammals. The studies that are

proposed will provide important new insight into the mechanisms through which endocrine-active environmental chemicals induce reproductive toxicities, and may, ultimately, lead to new strategies for detection and prevention of adverse effects in exposed individuals. In addition, the economic stimulatory impact is also expected to be major, advancing Recovery Act goals through the direct hiring of research staff to support the needs of this project and via the positive economic stimulus that will result from the expenditure of laboratory research supplies funds.

Scientific Articles from NIEHS

The NIEHS Division of Intramural Research investigators and their collaborators have published DES research findings in peer-reviewed journal articles. To find out more about these studies, please reference the following journal articles.

2010

1. D'Aloisio AA, Baird DD, DeRoo LA, Sandler DP. Association of intrauterine and early-life exposures with diagnosis of uterine leiomyomata by 35 years of age in the Sister Study. *Environ Health Perspect.* 2010: Mar. 118(3):375-81.
2. Steiner AZ, D'Aloisio AA, DeRoo LA, Sandler DP, Baird DD. Association of intrauterine and early-life exposures with age at menopause in the Sister Study. *Am J Epidemiol.* 2010: Jul 15;172(2):140-8.
3. Henley DV, Korach KS. Physiological effects and mechanisms of action of endocrine disrupting chemicals that alter estrogen signaling. *Hormones (Athens).* 2010: Jul-Sep;9(3):191-205.
4. Newbold RR. Impact of environmental endocrine disrupting chemicals on the development of obesity. *Hormones (Athens).* 2010: Jul-Sep;9(3):206-17.
5. Le HH, Belcher SM. Rapid signaling actions of environmental estrogens in developing granule cell neurons are mediated by estrogen receptor β . *Endocrinology.* 2010: Dec;151(12):5689-99.
6. Frawley R, White K Jr, Brown R, Musgrove D, Walker N, Germolec D. Gene expression alterations in immune system pathways in the thymus after exposure to immunosuppressive chemicals. *Environ Health Perspect.* 2011: Mar;119(3):371-6.

7. Doherty LF, Bromer JG, Zhou Y, Aldad TS, Taylor HS. In Utero Exposure to Diethylstilbestrol (DES) or Bisphenol-A (BPA) Increases EZH2 Expression in the Mammary Gland: An Epigenetic Mechanism Linking Endocrine Disruptors to Breast Cancer. *Horm Cancer*. 2010: Jun;1(3):146-55.

2009

1. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. *Mol Cell Endocrinol*. 2009: May 25;304(1-2):84-9.
2. Liu J, Yu L, Coppin JF, Tokar EJ, Diwan BA, Waalkes MP. Fetal arsenic exposure appears to facilitate endocrine disruption by postnatal diethylstilbestrol in neonatal mouse adrenal. *Chem Biol Interact*. 2009: Dec 10;182(2-3):253-8.

2008

1. Jukic AM, Weinberg CR, Wilcox AJ, McConnaughey DR, Hornsby P, Baird DD. Accuracy of reporting of menstrual cycle length. *Am J Epidemiol* 2008;167:25-33.
2. Tang, W.Y., Newbold R.R., Mardilovick K, and Ho. S.M. Persistent hypomethylation in the promoter of nucleosomal binding protein 1 (Nsbp 1) correlate with overexpression of Nsbp1 in mouse uteri neonatally exposed to diethylstilbestrol or genistein. *Endocrinology* 2008: 149(12): 6922-5931.

2007

1. Newbold, R.R., Jefferson, W.N., Grissom, S.F., Padilla-Banks, Snyder, R.J., and Lobenhofer, E. Developmental exposure to diethylstilbestrol (DES) alters uterine gene expression that may be associated with uterine neoplasia later in life. *Mol Carcinog*. 2007: 46:783-796.

2006

1. Bonde JP, Joffe M, Sallmen M, Kristensen P, Olsen J, Roeleveld N, Wilcox A. Validity issues relating to time-to-pregnancy studies of fertility. *Epidemiol* 2006: 17:347-9.
2. Nguyen RH, Wilcox AJ, Baird DD. Can men provide accurate confounder data about their partners for time-to-pregnancy studies? *Ann Epidemiol* 2006: 17:186-90.

2005

1. Baird, D.D. and Newbold, R.R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. *Reproductive Toxicology* 2005: 20, 81-84.

2004

1. Newbold, R.R., Jefferson, W.N., Padilla-Banks, E. and Haseman, J. Developmental exposure to diethylstilbestrol (DES) alters uterine response to estrogens in prepubescent mice: low versus high dose effects. *Reprod Toxicol.* 2004: 18, 399-406.

2002

1. Hall, J.M., Korach, K.S., Analysis of the molecular mechanisms of human estrogen receptors α and β : reveals differential specificity in target promoter regulation by endocrine disrupting chemicals. *J Biol Chem* 2002: 277: 44455-44461.
2. Newbold, R.R., Moore, A.B. and Dixon, D. Characterization of uterine leiomyomas in CD-1 mice following developmental exposure to diethylstilbestrol (DES). *Toxicol Pathol* 2002: 30, 611-6.

2001

1. Prins, G.S., Birch, L., Couse, J.F., Choi, I., Katzenellenbogen, B.S., Korach, K.S., Estrogen imprinting of the developing prostate gland is mediated through stromal estrogen receptor- α : studies with α ERKO and β ERKO mice. *Cancer Research* 2001: 61: 6089-6097.
2. Couse, J.F., Dixon, D., Yates, M., Moore, A.B., Ma, L., Maas, R., Korach, K.S., Estrogen receptor- α knockout mice exhibit resistance to the developmental effects of neonatal diethylstilbestrol exposure on the female reproductive tract. *Develop Biol.* 2001: 238: 224-238.
3. Li, S., Ma L., Chiang T., Burow M., Newbold R.R., Negishi M., Barrett J.C. and McLachlan J.A. Promoter CpG methylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure. *Mol Carcinog* 2001: 32, 213-9.

2000

1. Newbold, R.R., Hanson R.B., Jefferson W.N., Bullock B.C., Haseman J. and McLachlan J.A. Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol. *Carcinogenesis* 2000: 21, 1355-63.

1999

1. Yoshida, A., Newbold R.R. and Dixon D. Effects of neonatal diethylstilbestrol (DES) exposure on morphology and growth patterns of endometrial epithelial cells in CD-1 mice. *Toxicologic Pathology* 1999: 27, 325-333.

1998

1. Hornsby PP, Wilcox AJ, Weinberg C. Cigarette smoking and disturbance of menstrual function. *Epidemiol* 1998; 9:193-98.
2. Chae, K., Lindzey, J.K., McLachlan, J.A., Korach, K.S. Estrogen dependent gene regulation by an oxidative metabolite of diethylstilbestrol, DES-4',4''-quinone. *Steroids* 1998; 63: 149-157.
3. Kregel, J.H., Hodgin, J.B., Couse, J.F., Enmark, E., Warner, M., Sar, M., Korach, K.S., Gustafsson, J.A., Smithies, O., Generation and characterization of reproductive phenotypes in mice lacking estrogen receptor- β . *Proc. Natl. Aca. Sci.* 1998; 95: 15677-15682.
4. Newbold, R.R., Hanson R.B., Jefferson W.N., Bullock B.C., Haseman J. and McLachlan J.A. Increased tumors but uncompromised fertility in the female descendants of mice exposed developmentally to diethylstilbestrol. *Carcinogenesis* 1998; 19, 1655-63.

1997

1. Couse, J. F., Davis, D. L., Hanson, R. B., Jefferson, W. N., McLachlan, J. A., Bullock, B.C., Newbold, R. R., Korach, K. S., Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol. *Molecular Carcinogenesis* 1997; 19: 236-242.

1996

1. Baird DD, Wilcox AJ, Herbst AL. Self-reported allergy, infection and autoimmune diseases among men and women exposed in utero to diethylstilbestrol. *J Clin Epidemiol* 1996; 49:263-6.
2. Newbold, R.R. and McLachlan J.A. Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. *Progress in Clinical and Biological Research.* 1996: 394, 131-147.

1995

1. Hornsby PP, Wilcox AJ, Herbst AL. Onset of menopause in women exposed to diethylstilbestrol in utero. *Am J Obstet Gynecol* 1995; 172:92-95.
2. Wilcox AJ, Baird DD, Weinberg CR, Hornsby PP, Herbst AL. Fertility in men exposed prenatally to diethylstilbestrol. *New Engl J Med* 1995; 332:1411-16.
3. Wilcox AJ, Umbach DM, Hornsby PP, Herbst AL. Age at menarche among DES granddaughters. *Am J Obstet Gynecol* 1995; 173:835-6.

4. Rhee, C. K., Chae, K., Levy, L. A., Korach, K. S. Synthesis and estrogen receptor binding of fluorinated diethylstilbestrol derivatives. *Bioorg Medicinal Chem Lett.* 1995:5:133-138.
5. Newbold, R.R. Cellular and molecular effects of developmental exposure to diethylstilbestrol: implications for other environmental estrogens. *Environmental Health Perspectives* 1995: 103, 83-87.

1994

1. Hornsby PP, Wilcox AJ, Weinberg CR, Herbst AL. Effects on the menstrual cycle of in utero exposure to diethylstilbestrol. *Am J Obstet Gynecol* 1994:170:709-15.
2. Korach, K. S. Insights from the study of animals lacking functional estrogen receptor. *Science* 1994: 266: 1524-1527.
3. Beckman, W.C., Jr., Newbold R.R., Teng C.T. and McLachlan J.A. Molecular feminization of mouse seminal vesicle by prenatal exposure to diethylstilbestrol: altered expression of messenger RNA. *Journal of Urology* 1994: 151, 1370-1378.

1993

1. Lubahn, D. B., Moyer, J. S., Golding, T. S., Couse, J. F., Korach, K. S., Smithies, O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. *Proc. Natl. Aca. Sci.* 1993: 90: 11162-11166.
3. Holladay, S. D., Blaylock, B. L., Comment, C. E., Heindel, J. J., Fox, W. M., Korach, K. S., Luster, M. I. Selective prothymocyte targeting by prenatal diethylstilbestrol exposure. *Cell Immunology* 1993: 152: 131-142.

1992

1. Wilcox AJ, Maxey J, Herbst AL. Prenatal diethylstilbestrol exposure and performance on college entrance examinations. *Horm Behav* 1992:26:433-39.
2. Herbert, C. D., Endo, S., Korach, K. S., Boyd, J., Barrett, J. C., McLachlan, J. A., Newbold, R. R.: Characterization of Murine Cell Lines from Diethylstilbestrol Induced Uterine Endometrial Adenocarcinomas. *In Vitro Cellular and Developmental Biology* 1992: 28: 327-336.
3. Ignar-Trowbridge, D. M., Hughes, A. R., Putney, J. W. Jr., McLachlan, J. A. and Korach, K.S. Diethylstilbestrol stimulates persistent phosphatidylinositol lipid turnover by an estrogen receptor-mediated mechanism in mouse uterus. *Endocrinology* 1992: 129:2423-2430.

1991

1. Pylkkanen, L., Santti R., Newbold R.R. and McLachlan J.A. Regional differences in the prostate of the neonatally estrogenized mouse. *The Prostate* 1991: 18, 117-129.

1990

1. Newbold, R.R., Bullock B.C. and McLachlan J.A. Uterine adenocarcinoma in mice following developmental treatment with estrogens: a model for hormonal carcinogenesis. *Cancer Research* 1990: 50, 7677-7681.

1989

1. Newbold, R.R., Pentecost B.T., Yamashita S., Lum K., Miller J.V., Nelson P., Blair j., Kong H., Teng C. and McLachlan J.A. Female gene expression in the seminal vesicle of mice after prenatal exposure to diethylstilbestrol. *Endocrinology* 1989, 124, 2568-2576.

1988

1. Bullock, B.C. Newbold, R.R., Bullock B.C. and McLachlan J.A. Lesions of the testis and epididymis associated with prenatal diethylstilbestrol exposure. *Environmental Health Perspectives* 1988: 77, 29-32.
2. Pentecost, B.T., Newbold, R.R., Teng C.T. and McLachlan J.A. Prenatal exposure of male mice to diethylstilbestrol alters the expression of the lactotransferrin gene in seminal vesicles. *Molecular Endocrinology* 1988:2, 1243-1248.

1987

1. Newbold, R.R., Bullock B.C. and McLachlan J.A. Testicular tumors in mice exposed in utero to diethylstilbestrol. *Journal of Urology* 1987: 138, 1446-1450.

1986

1. Haney, A.F., Newbold R.R., Fetter B.F. and McLachlan J.A. Paraovarian cysts associated with prenatal diethylstilbestrol exposure: comparison of the human with a mouse model. *American Journal of Pathology* 1986: 124, 405-411.

1985

1. Korach, K. S. and McLachlan, J. A.: The role of the estrogen receptor in diethylstilbestrol toxicity. *Archives of Toxicology* 1985: 8: 33-42.
2. Korach, K. S., Fox-Davies, C., Quarmby, V. E., and Swaisgood, M. H.: Diethylstilbestrol metabolites and analogs: Biochemical probes for differential uterine estrogen responses. *J. Biol. Chem.* 1985: 261: 15420-15426.
3. Maier, D.B., Newbold R.R. and McLachlan J.A. Prenatal diethylstilbestrol exposure alters murine uterine responses to prepubertal estrogen stimulation. *Endocrinology* 1985: 116, 1878-1886.

4. Newbold, R.R., Bullock B.C. and McLachlan J.A. Lesions of the rete testis in mice exposed prenatally to diethylstilbestrol. *Cancer Research* 1985: 45, 5145-5150.
5. Newbold, R.R., Bullock B.C. and McLachlan J.A. Progressive proliferative changes in the oviduct of mice following developmental exposure to diethylstilbestrol. *Teratogenesis, Carcinogenesis, and Mutagenesis* 1985: 5, 473-480.

1984

1. Duax, W. L., Swenson, D. C., Strong, P. D., Korach, K. S., McLachlan, J. A., and Metzler, M.: Molecular structures of metabolites and analogues of diethylstilbestrol and their relationship to receptor binding and biological activity. *Mol. Pharmacol* 1984: 26: 520-525.
2. McLachlan, J. A., Korach, K. S., Newbold, R. R., and Degen, G. H.: Diethylstilbestrol and other estrogens in the environment. *Fund. Appl. Tox.* 1984: 4: 686-691.
3. Newbold, R.R., Bullock, B.C., and McLachlan, J.A. Animal model of human disease: diverticulosis and salpingitis isthmica nodosa (SIN) of the fallopian tube: estrogen-induced diverticulosis and SIN of the mouse oviduct. *American Journal of Pathology* 1984: 117: 333-335.

1983

1. Newbold, R.R., Bullock, B.C., and McLachlan, J.A. Exposure to diethylstilbestrol during pregnancy permanently alters the ovary and oviduct. *Biology of Reproduction* 1983: 28: 735-744.
2. Newbold, R.R., Tyrey, S., Haney, A.F., and McLachlan, J.A. Developmentally arrested oviduct: a structural and functional defect in mice following prenatal exposure to diethylstilbestrol. *Teratology* 1983: 27: 417-426.

1982

1. McLachlan, J.A., Newbold, R.R., Shah, H.C., Hogan, M., and Dixon, R.L. Reduced fertility in female mice exposed transplacentally to diethylstilbestrol. *Fertility and Sterility* 1982: 39: 364-371.
2. Newbold, R.R. and McLachlan, J.A. Vaginal adenosis and adenocarcinoma in mice exposed prenatally or neonatally to diethylstilbestrol. *Cancer Research* 1982: 42:2003-2011.

1980

1. McLachlan, J.A., Newbold, R.R. and Bullock, B.C. Long term effects on the female mouse genital tract associated with prenatal exposure to diethylstilbestrol. *Cancer Research* 1980: 40: 3988-3999.

1979

1. McLachlan, J. A., Baucom, K., Korach, K. S., Levy, L., and Metzler, M.: A novel fluorinated derivative of diethylstilbestrol. *Steroids* 1979: 33: 543-547.
2. Korach, K. S., Metzler, M., and McLachlan, J. A.: Diethylstilbestrol metabolites and analogs: New probes for the study of hormone action. *J. Biol. Chem* 1979: 254: 8963-8968.

1978

1. Korach, K. S., Metzler, M., and McLachlan, J. A.: Estrogenic activity in vivo and in vitro of some diethylstilbestrol metabolites and analogs. *Proc. Natl. Acad. Sci. USA* 1978: 75: 468-471..

1975

1. McLachlan, J.A. and Newbold, R.R. Reproductive tract lesions in male mice exposed prenatally to diethylstilbestrol. *Science* 1975: 190:991-992.

Grantees funded through the NIEHS Division of Extramural Research and Training have published research findings in peer-reviewed journal articles. To find out more about these studies, please reference the following journal articles.

2011

1. Hannas BR, Wang YH, Thomson S, Kwon G, Li H, Leblanc GA. Regulation and dysregulation of vitellogenin mRNA accumulation in daphnids (*Daphnia magna*). *Aquat Toxicol.* 2011 Jan 25;101(2):351-7.
2. Hayashi K, Yoshioka S, Reardon SN, Rucker EB 3rd, Spencer TE, DeMayo FJ, Lydon JP, MacLean JA 2nd. WNTs in the neonatal mouse uterus: potential regulation of endometrial gland development. *Biol Reprod.* 2011 Feb;84(2):308-19.

2010

1. Elisa M Jorgensen; Jane I Ruman; Leo Doherty; Hugh S Taylor. A novel mutation of HOXA13 in a family with hand-foot-genital syndrome and the role of polyalanine expansions in the spectrum of Müllerian fusion anomalies. *Fertil Steril.* 2010 Sep;94(4):1235-8.

2. Susan M Kiefer; Lynn Robbins; Kelly M Stumpff; Congxing Lin; Liang Ma; Michael Rauchman. Sall1-dependent signals affect Wnt signaling and ureter tip fate to initiate kidney development. *Development*. 2010 Sep;137(18):3099-106.
3. Jason G Bromer; Yuping Zhou; Melissa B Taylor; Leo Doherty; Hugh S Taylor. Bisphenol-A exposure in utero leads to epigenetic alterations in the developmental programming of uterine estrogen response. *FASEB J*. 2010 Jul;24(7):2273-80.
4. Bredfeldt TG, Greathouse KL, Safe SH, Hung MC, Bedford MT, Walker CL. Xenoestrogen-induced regulation of EZH2 and histone methylation via estrogen receptor signaling to PI3K/AKT. *Mol Endocrinol*. 2010 May;24(5):993-1006.

2009

1. Congxing Lin; Yan Yin; G Michael Veith; Alexander V Fisher; Fanxin Long; Liang Ma. Temporal and spatial dissection of Shh signaling in genital tubercle development. *Development*. 2009 Dec;136(23):3959-67.
2. Amy M Tetrault; Susan M Richman; Xiaolan Fei; Hugh S Taylor. Decreased endometrial HOXA10 expression associated with use of the copper intrauterine device. *Fertil Steril*. 2009 Dec;92(6):1820-4.
3. Mathews E, Braden TD, Williams CS, Williams JW, Bolden-Tiller O, Goyal HO. Maldevelopment of the penis and loss of fertility in male rats treated neonatally with female contraceptive 17alpha-ethinyl estradiol: a dose-response study and a comparative study with a known estrogenic teratogen diethylstilbestrol. *Toxicol Sci*. 2009 Dec;112(2):331-43.
4. Liang Ma. Endocrine disruptors in female reproductive tract development and carcinogenesis. *Trends Endocrinol Metab*. 2009 Sep;20(7):357-63.
5. Goyal HO, Braden TD, Williams CS, Williams JW. Estrogen-induced developmental disorders of the rat penis involve both estrogen receptor (ESR)- and androgen receptor (AR)-mediated pathways. *Biol Reprod*. 2009 Sep;81(3):507-16.
6. Kathleen A Connell; Marsha K Guess; Heidi W Chen; Tara Lynch; Richard Bercik; Hugh S Taylor. HOXA11 promotes fibroblast proliferation and regulates p53 in uterosacral ligaments. *Reprod Sci*. 2009 Jul;16(7):694-700.
7. Hsu PY, Deatherage DE, Rodriguez BA, Liyanarachchi S, Weng YI, Zuo T, Liu J, Cheng AS, Huang TH. Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells. *Cancer Res*. 2009 Jul 15;69(14):5936-45.
8. Liren Liu; Sharrell Lee; Jianxuan Zhang; Sara B Peters; Jeffrey Hannah; Yue Zhang; Yan Yin; Andrew Koff; Liang Ma; Pengbo Zhou. CUL4A abrogation augments DNA damage

response and protection against skin carcinogenesis. *Mol Cell*. 2009 May 14;34(4):451-60.

9. Congxing Lin; Yan Yin; Hong Chen; Alexander V Fisher; Feng Chen; Michael Rauchman; Liang Ma. Construction and characterization of a doxycycline-inducible transgenic system in Msx2 expressing cells. *Genesis*. 2009 May;47(5):352-9.
10. Kathleen A Connell; Marsha K Guess; Alison Tate; Vaagn Andikyan; Richard Bercik; Hugh S Taylor. Diminished vaginal HOXA13 expression in women with pelvic organ prolapse. *Menopause*. 2009 May-Jun;16(3):529-33.
11. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr*. 2009 Apr;21(2):243-51.
12. Jing Cai; Jonghyeob Lee; Raphael Kopan; Liang Ma. Genetic interplays between Msx2 and Foxn1 are required for Notch1 expression and hair shaft differentiation. *Dev Biol*. 2009 Feb 15;326(2):420-30.
13. Banghyun Lee; Hongling Du; Hugh S Taylor. Experimental murine endometriosis induces DNA methylation and altered gene expression in eutopic endometrium. *Biol Reprod*. 2009 Jan;80(1):79-85.

2008

1. Congxing Lin; Yan Yin; Fanxin Long; Liang Ma. Tissue-specific requirements of beta-catenin in external genitalia development. *Development*. 2008 Aug;135(16):2815-25.
2. Kathleen A Connell; Marsha K Guess; Heidi Chen; Vaagn Andikyan; Richard Bercik; Hugh S Taylor. HOXA11 is critical for development and maintenance of uterosacral ligaments and deficient in pelvic prolapse. *J Clin Invest*. 2008 Mar;118(3):1050-5.
3. Hugh S Taylor. Endocrine disruptors affect developmental programming of HOX gene expression. *Fertil Steril*. 2008 Feb;89(2 Suppl):e57-8.
4. Yung-Chieh Tan; Amy Q Shen; Yu Li; Elliot Elson; Liang Ma. Engineering lipid tubules using nano-sized building blocks: the combinatorial self-assembly of vesicles. *Lab Chip*. 2008 Feb;8(2):339-45.
5. Yan Yin; Wei-Wei Huang; Congxing Lin; Hong Chen; Alex MacKenzie; Liang Ma. Estrogen suppresses uterine epithelial apoptosis by inducing birc1 expression. *Mol Endocrinol*. 2008 Jan;22(1):113-25.

2007

1. Gaurang S Daftary; Umit Kayisli; Emre Seli; Orhan Bukulmez; Aydin Arici; Hugh S Taylor. Salpingectomy increases peri-implantation endometrial HOXA10 expression in women with hydrosalpinx. *Fertil Steril*. 2007 Feb;87(2):367-72.
2. G Eda Akbas; Xiaolan Fei; Hugh S Taylor. Regulation of HOXA10 expression by phytoestrogens. *Am J Physiol Endocrinol Metab*. 2007 Feb;292(2):E435-42.
3. Caroline C Smith; Hugh S Taylor. Xenoestrogen exposure imprints expression of genes (Hoxa10) required for normal uterine development. *FASEB J*. 2007 Jan;21(1):239-46.

2006

1. Yan Yin; Congxing Lin; Liang Ma. MSX2 promotes vaginal epithelial differentiation and wolffian duct regression and dampens the vaginal response to diethylstilbestrol. *Mol Endocrinol*. 2006 Jul;20(7):1535-46.
2. Jennifer L Sarno; Frederick Schatz; Charles J Lockwood; S-T Joseph Huang; Hugh S Taylor. Thrombin and interleukin-1beta regulate HOXA10 expression in human term decidua: implications for preterm labor. *J Clin Endocrinol Metab*. 2006 Jun;91(6):2366-72.
3. Gaurang S Daftary; Hugh S Taylor. Endocrine regulation of HOX genes. *Endocr Rev*. 2006 Jun;27(4):331-55.
4. Michael Kelly; Gaurang Daftary; Hugh S Taylor. An autoregulatory element maintains HOXA10 expression in endometrial epithelial cells. *Am J Obstet Gynecol*. 2006 Apr;194(4):1100-7; discussion 1107-9.

2005

1. Hongling Du; Gaurang S Daftary; Sasmira I Lalwani; Hugh S Taylor. Direct regulation of HOXA10 by 1,25-(OH)₂D₃ in human myelomonocytic cells and human endometrial stromal cells. *Mol Endocrinol*. 2005 Sep;19(9):2222-33.
2. Xiaolan Fei; Hajin Chung; Hugh S Taylor. Methoxychlor disrupts uterine Hoxa10 gene expression. *Endocrinology*. 2005 Aug;146(8):3445-51.
3. Jennifer L Sarno; Harvey J Kliman; Hugh S Taylor. HOXA10, Pbx2, and Meis1 protein expression in the human endometrium: formation of multimeric complexes on HOXA10 target genes. *J Clin Endocrinol Metab*. 2005 Jan;90(1):522-8.

2004

1. Danielle B Lane; Thomas J Rutherford; Hugh S Taylor. HOXA10 expression in endometrial adenocarcinoma. *Tumour Biol.* 2004 Sep-Dec;25(5-6):264-9.
2. G Eda Akbas; Joon Song; Hugh S Taylor. A HOXA10 estrogen response element (ERE) is differentially regulated by 17 beta-estradiol and diethylstilbestrol (DES). *J Mol Biol.* 2004 Jul 23;340(5):1013-23.
3. Hugh S Taylor. Endometrial cells derived from donor stem cells in bone marrow transplant recipients. *JAMA.* 2004 Jul 7;292(1):81-5.
4. Micheline C Chu; F Belgin Selam; Hugh S Taylor. HOXA10 regulates p53 expression and matrigel invasion in human breast cancer cells. *Cancer Biol Ther.* 2004 Jun;3(6):568-72.

2003

1. Dilek Cermik; Belgin Selam; Hugh S Taylor. Regulation of HOXA-10 expression by testosterone in vitro and in the endometrium of patients with polycystic ovary syndrome. *J Clin Endocrinol Metab.* 2003 Jan;88(1):238-43.